This study has been set up within the framework of the INNODIA network. INNODIA is a global
partnership between 31 academic institutions, 6 industrial partners, a small sized enterprise
and 2 patient organizations, bringing their knowledge and experience together with one common
goal: "To fight type 1 diabetes". (www.innodia.eu) The overall aim of INNODIA is to advance
in a decisive way how to predict, stage, evaluate and prevent the onset and progression of
type 1 diabetes (T1D).
For this, INNODIA has established a comprehensive and interdisciplinary network of clinical
and basic scientists, who are leading experts in the field of T1D research in Europe and UK
(United Kingdom), with complementary expertise from the areas of immunology, Beta-cell
biology, biomarker research and T1D therapy, joining forces in a coordinated fashion with
industry partners and two foundations, as well as with all major stakeholders in the process,
including regulatory bodies and patients with T1D and their families.